 Effects recombinant human erythropoietin cerebral cutaneous blood flow blood coagulability Seizures hypertensive encephalopathy transient ischemic attacks thrombosis hemodialysis accesses early clinical trials recombinant human erythropoietin events hematocrit value direct effect recombinant human hormone transfusion-dependent hemodialysis patients groups serum ferritin concentration group microgram/liter group micrograms/liter month placebo administration recombinant human erythropoietin U/kg months month Hematocrit values mean SD dose adjustment group thrice weekly phlebotomies group constant dose erythropoietin Viscosity subnormal normal group cerebral blood flow normal normal group minor insignificant changes viscosity reciprocal changes cerebral blood flow change group transcutaneous oxygen tension Bleeding time normal groups recombinant human erythropoietin administration changes statistical significance Fibrinogen levels patients unchanged significant coagulation-related changes Recombinant erythropoietin dosage schedule administration study changes seizures intravascular thrombosis